Briumvi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0011 
B.II.e.5.a.2 - Change in pack size of the finished 
16/02/2024 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
SmPC, Annex 
II, Labelling 
and PL 
IB/0008 
B.I.a.1.k - Change in the manufacturer of AS or of a 
22/01/2024 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IAIN/0010/G 
This was an application for a group of variations. 
18/01/2024 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0009 
B.II.b.5.c - Change to in-process tests or limits 
11/01/2024 
n/a 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
II/0006 
B.I.a.1.j - Change in the manufacturer of AS or of a 
11/01/2024 
n/a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
12/12/2023 
n/a 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0003 
B.I.b.2.d - Change in test procedure for AS or 
07/12/2023 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0004 
B.I.a.2.a - Changes in the manufacturing process of 
20/11/2023 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IA/0005 
B.I.b.2.a - Change in test procedure for AS or 
09/11/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
II/0001 
B.II.d.1.f - Change in the specification parameters 
09/11/2023 
n/a 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
T/0002 
Transfer of Marketing Authorisation 
22/09/2023 
09/10/2023 
SmPC, 
Labelling and 
PL 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
